The J.P. Morgan Healthcare Conference in San Francisco is back for 2025 and here at Fierce Biotech, we’re going to bring you all the latest updates live from the life sciences event of the year.
As is tradition, we’ve already had a few notable mid-range deals and some bumper biotech fund raises in the week leading up to the event. This included Lonza's Synaffix adding Boehringer to its constellation of partners with a $1.3 billion ADC tech pact, with Roche following suit in that space, penning a potential $780 million ADC deal with Chugai, as Sanofi inked a $400 million biobucks pact with Alloy’s antisense platform.
There was also a major $410 million venture raise for oral GLP-1 player Verdiva as neurological focused Tenvie launched with a cool $200 million.
But where the biotech gods giveth, they also taketh away. There was some major pruning across multiple biotechs, including for Intellia, Galapagos, Cassava, Scribe IGM, Y-mAbs and Passage Bio, as they streamline into 2025.
What can we expect from the conference itself? The Fierce team will be on the ground hunting down the biggest announcements and interviews, as well as running our own events, so stay tuned.
Check out our daily updates below for all the latest from JPM today and come back each day this week for your roundups.
Monday 4:30 a.m. ET Jan. 13
Tune Therapeutics enters the JPM dance floor with a bumper $175 million series B raise for its epigenetic silencing drug against chronic hepatitis B. Story.
Monday 2:30 a.m. ET Jan. 13
German pharma Bayer also comes out the gates at pace with news that its BlueRock Parkinson’s disease cell therapy is moving into late-stage testing, with that trial set to be the first registrational phase 3 for an investigational allogeneic cell therapy in the area.
Monday 2:00 a.m. ET Jan. 13
GSK clearly wanted an early run at the news cycle, sending word early Monday morning that it had tied up a GI cancer buyout deal with biotech IDRx worth up to $1.15 billion. Story.
Saturday 6:00 a.m. ET Jan. 10
Gilead roared into JPM25 with a major $1.7 billion deal, that includes a huge $250 million upfront, for access to Leo Pharma's preclinical inflammation drugs. Story.
https://www.fiercebiotech.com/biotech/jpm25-day-1-fierce-biotech-daily-roundup
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.